|Bid||202.00 x 1100|
|Ask||202.50 x 1100|
|Day's Range||200.84 - 203.80|
|52 Week Range||198.64 - 276.69|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||16.77|
|Forward Dividend & Yield||7.04 (3.37%)|
|Ex-Dividend Date||Aug 16, 2021|
|1y Target Est||N/A|
Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, and virtually, from Dec. 11-14, 2021.
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022. The dividend will be paid on March 8, 2022, to all stockholders of record as of the close of business on February 15, 2022. This represents a 10% increase from that paid in each of the previous four quarters.
Amgen (NASDAQ: AMGN) today announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla® (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement, compared with placebo, in the primary endpoint of the modified static